The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
In September 2010, Labcorp acquired Genzyme Genetics, formerly a division of Genzyme Corporation, with 9 testing laboratories and approximately 1,900 employees, for $925 million in cash. In February 2011, Labcorp acquired the assets of bankrupt Westcliff Medical Laboratory. The FTC challenged the acquisition but lost in court. In June 2011, Labcorp acquired Canadian central labs partner Clearstone from Czura Thornton, adding laboratories in China, France, Singapore and Canada, and the central laboratory protocol management system APOLLO CLPM. In November 2011, Labcorp acquired more than 90% of the shares of DNA testing company Orchid Cellmark for $85 million. To receive approval of the transaction from the Federal Trade Commission, Labcorp sold parts of Orchid's DNA paternity testing business to DNA Diagnostics Center. In May 2012, Labcorp Clinical Trials sold its European biological sampling kit building operation located in Hamburg to Marken. In August 2012, Labcorp acquired testing lab Medtox Scientific for $241 million. In September 2013, Labcorp acquired MuirLab, the clinical laboratory outreach business of John Muir Health. In November 2014, Labcorp acquired LipoScience, a developer of diagnostic tests based on nuclear magnetic resonance spectroscopy measuring heart disease risk, for $85 million. In December 2014, Labcorp acquired Bode Technology Group, a provider of forensic DNA analysis, DNA collection products, and relationship testing and the largest DNA forensic testing company in the U.S., from SolutionPoint International.
== Applications of commercially synthesized peptides == Biologically active peptides have been integrated into a growing number of active pharmaceutical ingredients (API’s) as well as standalone products such as vasopressin, gonadorelin, leuprolide, and goserelin. Completion of the Human Genome Project resulted in the identification of approximately 30,000 proteins encoded in the human genome and provided many more new target molecules for biomedical researchers to explore. To investigate the possibility of increasing the native potency of a given peptide or protein using a rational design approach, small and large amounts of peptides are needed, Some in the milligram scale. Once a desired activity or potency is identified, larger scale synthesis is need. For this, gram to multi-gram scale may be needed in order to initiate small animal studies. Often, after successful validation, an even larger scale of synthesis may be desired. These can range in scale from hundreds of grams to multi-kilo amounts.
Large bodies of research are devoted to using genetic markers to predict whether patients will respond to SSRIs or have side effects that will cause their discontinuation, although these tests are not yet ready for widespread clinical use.
Sources: en.wikipedia.org
The city of Le Havre has some of the oldest sports clubs in France: the Le Havre Rowing Society (1838), the Regatta Society of Le Havre (1838), and Le Havre Athletic Club (1872), doyen of French football and rugby clubs. The city also hosted the sailing events for the 1900 and 1924 Summer Olympics, respectively. Le Havre is dominated by three professional sports teams: the first is the Le Havre AC football team who were relegated from Ligue 1 after the 2008–2009 season but gained promotion back to Ligue 1 in 2023. Its training centre is well-reputed for having trained a number of international French players, including Vikash Dhorasoo, Julien Faubert, Jean-Alain Boumsong, Lassana Diarra, and Steve Mandanda. The second major sports team is Saint Thomas Basketball who represent the city in LNB Pro A. Thirdly the HAC women's team who play in the first division with many international players in its ranks. The team won their first major national title, the Coupe de France for women's handball in 2006. Le Havre Rugby athletic club plays in Fédérale 3 (equivalent to fifth division). The Hockey Club of Le Havre played at the fourth level nationally (Division 3) for the 2008–2009 season. The team is nicknamed the "Dock's du Havre". The maritime side of the city is found in many sports: for example, the tradition of sailing is old. On 29 July 1840 the first French pleasure boat regatta was held. Today, Le Havre is known as a water sports and Seaside resort. The marina can host deepwater vessels around the clock in any weather.
The most recognizable and most common form of dwarfism in humans is achondroplasia, which accounts for 70% of dwarfism cases, and occurs in 4 to 15 out of 100,000 live births. It produces rhizomelic short limbs, increased spinal curvature, and distortion of skull growth. In achondroplasia the body's limbs are proportionately shorter than the trunk (abdominal area), with a larger head than average and characteristic facial features. Achondroplasia is an autosomal dominant disorder caused by the presence of an altered allele in the genome. If a pair of achondroplasia alleles are present, the result is fatal, usually perinatally. Achondroplasia is a mutation in the fibroblast growth factor receptor 3. In the context of achondroplasia, this mutation causes FGFR3 to become constitutively active, inhibiting bone growth.
The application of nuclear magnetic resonance best known to the general public is magnetic resonance imaging for medical diagnosis and magnetic resonance microscopy in research settings. However, it is also widely used in biochemical studies, notably in NMR spectroscopy such as proton NMR, carbon-13 NMR, deuterium NMR and phosphorus-31 NMR. Biochemical information can also be obtained from living tissue (e.g. human brain tumors) with the technique known as in vivo magnetic resonance spectroscopy or chemical shift NMR microscopy. These spectroscopic studies are possible because nuclei are surrounded by orbiting electrons, which are charged particles that generate small, local magnetic fields that add to or subtract from the external magnetic field, and so will partially shield the nuclei. The amount of shielding depends on the exact local environment. For example, a hydrogen bonded to an oxygen will be shielded differently from a hydrogen bonded to a carbon atom. In addition, two hydrogen nuclei can interact via a process known as spin–spin coupling, if they are on the same molecule, which will split the lines of the spectra in a recognizable way. As one of the two major spectroscopic techniques used in metabolomics, NMR is used to generate metabolic fingerprints from biological fluids to obtain information about disease states or toxic insults.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.